Cardiawave

Executive Summary

Cardiawave is a French medical device company pioneering a non-invasive ultrasound therapy (NIUT) for calcific aortic stenosis, a common and life-threatening heart valve disease. The company's proprietary technology uses focused ultrasound to soften calcified valve leaflets, restoring function without surgery or catheterization. This approach targets the large unmet need among elderly patients who are often ineligible for invasive procedures. Founded in 2015 and based in Paris, Cardiawave has progressed through early feasibility studies and is now advancing toward pivotal clinical trials. The company’s technology has the potential to transform the standard of care by offering a truly non-invasive alternative, reducing hospital stays and complications. With an aging global population and rising prevalence of aortic stenosis, Cardiawave addresses a multi-billion-dollar market opportunity. The company has secured patent protection and is actively engaging with regulatory authorities to bring its therapy to patients. While still in the development stage, Cardiawave's innovation and clinical progress position it as a compelling player in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q2 2026Pivotal trial enrollment completion70% success
• Q4 2026CE Mark submission for European approval60% success
• Q3 2026Series C funding round close80% success